Estrogen and progestogen inhibit NF-κB in atherosclerotic tissues of ovariectomized ApoE (−/−) mice

Climacteric

Volumn 19, Issue 4, 2016, Pages 357-363

  Chen, Y ^a   Zhao, H ^b   Ren, X ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

atherosclerosis; Estrogen; MMP 9; NF B; progestogen

Indexed keywords

APOLIPOPROTEIN E; DYDROGESTERONE; ESTRADIOL VALERATE; ESTROGEN RECEPTOR BETA; FOLLITROPIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUTEINIZING HORMONE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MESSENGER RNA; NFKB1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; EMBRYO; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; IMMUNOFLUORESCENCE; MOUSE; MOUSE EMBRYONIC STEM CELL; NONHUMAN; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INFLAMMATION; METABOLISM; OVARIECTOMY;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DYDROGESTERONE; ESTRADIOL; ESTROGENS; FEMALE; INFLAMMATION; MATRIX METALLOPROTEINASE 9; MICE; NF-KAPPA B P50 SUBUNIT; OVARIECTOMY; PROGESTINS; RECEPTORS, ESTROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84965003795     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2016.1167867     Document Type: Article

References (30)

1. D.Mozaffarian, E.J.Benjamin, A.S.Go, et al. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation 2015;131:e29–322
2. L.J.Shaw, R.Bugiardini, C.N.Merz Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol 2009;54:1561–75
3. M.Barylski, D.P.Mikhailidis, M.Ciebiada, J.Rysz, M.Banach Gender differences in the treatment of ischemic heart disease. Curr Pharm Des 2011;17:1059–69
4. A.Towfighi, L.Zheng, B.Ovbiagele Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med 2009;169:1762–6
5. J.G.Canto, W.J.Rogers, R.J.Goldberg, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA 2012;307:813–22
6. C.N.Bairey Merz, L.J.Shaw, S.E.Reis, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Part II. Gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006;47:S21–S9
7. A.J.Lansky, V.G.Ng, A.Maehara, et al. Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. JACC Cardiovasc Imaging 2012;5:S62–S72
8. J.Dabek, A.Kulach, Z.Gasior Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB): a new potential therapeutic target in atherosclerosis? Pharmacol Rep 2010;62:778–83
9. B.Pamukcu, G.Y.Lip, E.Shantsila The nuclear factor-kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res 2011;128:117–23
10. B.Mittal, A.Mishra, A.Srivastava, S.Kumar, N.Garg Matrix metalloproteinases in coronary artery disease. Adv Clin Chem 2014;64:1–72
11. A.Mishra, A.Srivastava, T.Mittal, N.Garg, B.Mittal Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients. Clin Chim Acta 2012;413:1668–74
12. M.H.Tayebjee, G.Y.Lip, R.J.MacFadyen Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. Curr Med Chem 2005;12:917–25
13. E.C.Vasquez, V.A.Peotta, A.L.Gava, T.M.Pereira, S.S.Meyrelles Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse. J Biomed Sci 2012;19:22
14. M.S.Cola, A.L.Gava, S.S.Meyrelles, E.C.Vasquez Endothelial dysfunction of resistance vessels in female apolipoprotein E-deficient mice. Lipids Health Dis 2010;9:51
15. J.E.Fata, V.Chaudhary, R.Khokha Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17beta-estradiol during the estrous cycle. Biol Reprod 2001;65:680–8
16. C.J.Haines, S.F.Yim, J.E.Sanderson The effect of continuous combined hormone replacement therapy on arterial reactivity in postmenopausal women with established angina pectoris. Atherosclerosis 2001;159:467–70
17. U.Sadat, F.A.Jaffer, M.A.van Zandvoort, et al. Inflammation and neovascularization intertwined in atherosclerosis: imaging of structural and molecular imaging targets. Circulation 2014;130:786–94
18. J.Hartman, W.H.Frishman Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 2014;22:147–51
19. I.Pateras, C.Giaginis, C.Tsigris, E.Patsouris, S.Theocharis NF-kappaB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links. Expert Opin Ther Targets 2014;18:1089–101
20. B.Mallavia, C.Recio, A.Oguiza, et al. Peptide inhibitor of NF-kappaB translocation ameliorates experimental atherosclerosis. Am J Pathol 2013;182:1910–21
21. Y.N.Yang, J.Y.Zhang, Y.T.Ma, et al. -94 ATTG insertion/deletion polymorphism of the NFKB1 gene is associated with coronary artery disease in Han and Uygur women in China. Genet Test Mol Biomarkers 2014;18:430–8
22. R.Deshpande, H.Khalili, R.G.Pergolizzi, S.D.Michael, M.D.Chang Estradiol down-regulates LPS-induced cytokine production and NFkB activation in murine macrophages. Am J Reprod Immunol 1997;38:46–54
23. H.N.Hodis, W.J.Mack Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. J Steroid Biochem Mol Biol 2014;142:68–75
24. J.R.Nofer Estrogens and atherosclerosis: insights from animal models and cell systems. J Mol Endocrinol 2012;48:R13–29
25. J.F.Arnal, H.Laurell, C.Fontaine, et al. Estrogen receptor actions on vascular biology and inflammation: implications in vascular pathophysiology. Climacteric 2009;12(Suppl 1):12–17
26. A.Munshi, V.Sharma, S.Kaul, et al. Estrogen receptor alpha genetic variants and the risk of stroke in a South Indian population from Andhra Pradesh. Clin Chim Acta 2010;411:1817–21
27. M.K.Osako, H.Nakagami, N.Koibuchi, et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 2010;107:466–75
28. R.C.Christian, P.Y.Liu, S.Harrington, et al. Intimal estrogen receptor (ER)beta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women. J Clin Endocrinol Metab 2006;91:2713–20
29. L.M.Pompei, M.L.Steiner, T.R.Theodoro, et al. Effect of estrogen therapy on vascular perlecan and metalloproteinases 2 and 9 in castrated rats. Climacteric 2013;16:147–53
30. K.C.Lewandowski, J.Komorowski, D.P.Mikhalidis, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 2006;91:3123–30